Rain Therapeutics Inc.
NASDAQ:RAIN
4.38 (USD) • At close September 2, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.003 | 0.003 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.003 | -0.003 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.98 | 16.677 | 19.078 | 14.51 | 14.257 | 13.555 | 14.672 | 15.284 | 5.489 | 5.328 | 4.172 | 7.893 | 1.473 | 1.762 |
| General & Administrative Expenses
| 1.069 | 1.342 | 1.15 | 3 | 0 | 0 | 0.043 | 4.113 | 5.414 | 5.066 | 4.479 | 3.901 | 3.461 | 3.895 | 3.405 | 3.154 | 2.7 | 1.48 | 1.28 | 0.591 | 1.119 | 0.668 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1.069 | 1.342 | 1.15 | 3 | 1.081 | 0.338 | 0.043 | 0.028 | 5.414 | 5.066 | 4.479 | 3.901 | 3.461 | 3.895 | 3.405 | 3.154 | 2.7 | 1.48 | 1.28 | 0.591 | 1.119 | 0.668 |
| Other Expenses
| 0.004 | 0 | 0.012 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001 | 0 | 0 | 0 | 0 | -0.005 | 0 |
| Operating Expenses
| 1.073 | 1.342 | 1.162 | 3 | 1.081 | 0.338 | 0.043 | 8.078 | 20.394 | 21.743 | 23.557 | 18.411 | 17.718 | 17.45 | 18.077 | 18.438 | 8.189 | 6.808 | 5.452 | 8.484 | 2.592 | 2.43 |
| Operating Income
| -1.073 | -1.345 | -1.162 | -3 | -1.081 | -0.338 | -0.043 | -0.028 | -23.231 | -21.743 | -23.557 | -18.411 | -17.718 | -17.45 | -18.077 | -18.438 | -8.189 | -6.808 | -5.452 | -8.484 | -2.592 | -2.43 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.12 | -0.137 | -0.008 | -0.007 | 0.646 | 0.096 | -0.007 | -0.007 | 1.167 | 1.259 | 0.882 | 0.37 | 0.107 | 0.056 | 0.094 | 0.012 | 0.006 | 0.008 | 0.009 | -1.962 | -0.032 | -0.139 |
| Income Before Tax
| -0.953 | -1.482 | -1.17 | -3.008 | -0.435 | -0.242 | -0.05 | -7.034 | -22.064 | -20.484 | -22.675 | -18.041 | -17.611 | -17.394 | -17.983 | -18.426 | -8.183 | -6.8 | -5.443 | -10.446 | -2.624 | -2.569 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.154 | 0 | -1.259 | 0.003 | -0.37 | -0.107 | -0.056 | 0.002 | 0.001 | 0.006 | 0.008 | 0.009 | 0 | 0 | 0 |
| Net Income
| -0.953 | -1.482 | -1.17 | -3.008 | -0.435 | -0.242 | -0.05 | -0.035 | -22.064 | -19.225 | -22.678 | -17.671 | -17.504 | -17.338 | -17.985 | -18.426 | -8.183 | -6.8 | -5.443 | -10.446 | -2.624 | -2.569 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.13 | -0.75 | -0.6 | -0.44 | -0.066 | -0.037 | -0.007 | -0.005 | -3.66 | -3.18 | -4.2 | -4.02 | -3.96 | -3.9 | -4.08 | -4.2 | -2.34 | -1.56 | -3.06 | -5.88 | -1.5 | -1.44 |
| EPS Diluted
| -0.13 | -0.75 | -0.6 | -0.44 | -0.066 | -0.037 | -0.007 | -0.005 | -3.66 | -3.18 | -4.2 | -4.02 | -3.96 | -3.9 | -4.08 | -4.2 | -2.34 | -1.56 | -3.06 | -5.88 | -1.5 | -1.44 |
| EBITDA
| -0.917 | -1.345 | -1.159 | -3 | -0.435 | -0.242 | -0.04 | 0.633 | -17.54 | -21.725 | -23.539 | -18.393 | -17.696 | -17.428 | -17.983 | -18.405 | -8.169 | -6.785 | -5.431 | -10.362 | -2.579 | -2.523 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |